HeyJaredJeff Craven
- Indexed articles, last 90 days
- 12
- Latest publication
- Aug 24, 2026
- Outlet visibility, for Raps
- Top 1M sites
- Earliest in this view
- Aug 10, 2026
Latest articles
Recon: FDA clears Roche, Lilly Alzheimerâs blood tests; Regenxbio gene therapy trial halted by FDA again (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates â big and small â on FDA, drug, and medical device regulation, and what weâre reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
Experts discusses need to modernize evidentiary models in rare diseases (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates â big and small â on FDA, drug, and medical device regulation, and what weâre reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
Recon: FDA approves Ultragenyx gene therapy for glycogen storage disorder; Overton faces confirmation challenges (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
Study highlights difficulty of measuring non-clinical factors that could influence FDA drug approval decisions (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
Recon: FDA releases draft guidance on gen AI-enabled devices; Industry warns Germany must reform drug pricing (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For Raps, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.